In Q1 2025, Tris also plans to share results evaluating cebranopadol in two additional studies... (Businesswire) - Jan 22, 2025 - "In Q1 2025, Tris also plans to share results evaluating cebranopadol in two additional studies, an intranasal human abuse potential study and ALLEVIATE-2, a Phase 3 clinical study in patients following bunionectomy, with an NDA submission expected later this year. Tris plans to conduct cebranopadol studies in multiple chronic pain indications beginning in the second half of 2025."
FDA filing • New trial • P1 data • Pain
|